A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
Completed · Phase 3 · NCT05526521
Conditions: Chronic Spontaneous Urticaria
At a glance
- Research payments reported, 2025
- $152,580
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- Sanofi
- Tested
- Dupilumab (drug)
- Dates
- Started 2022-08-25; completion 2025-02-03
- Results posted
- Yes
This was a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study was to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details included: Screening: 2 to 4 weeks; The treatment duration was 24 weeks; Follow-up period: 12 weeks; The study duration was 38 to 40 weeks (including screening and follow-up); The number of study visits was 6.
From ClinicalTrials.gov, last updated 2025-11-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $152,580 in research payments for this study in 2025 (18 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Neetu Talreja, MD Hospitalist · Detroit, MI
- Jeffrey R. Stokes, MD Pediatric Pulmonology · Saint Louis, MO
- Joyce E. Yu, MD Allergy & Immunology · New York, NY
- Lisa M. Sammon, DO Allergy & Immunology · Akron, OH
- Justin T. Schwartz, M.D./PH.D Pediatrics · Cincinnati, OH
- Iftikhar Hussain, MD Allergy & Immunology · Tulsa, OK
- Rachel G. Robison, M.D. Pediatrics · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Akron Children's Hospital, OH $59,330
- Cincinnati Children's Hospital Medical Center, OH $34,731
- Treasure Valley Medical Research Neetu Talreja $19,632
- The Trustees of Columbia University in The City of New York $18,950
- Vital Prospects Clinical Research I Institute PC $10,587
- Washington University $5,848
- Vanderbilt University Medical Center, TN $3,502
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.